Neurocognitive dysfunction in survivors of childhood brain tumors.
Newer treatments have resulted in increasing numbers of survivors of childhood cancer, for whom neurological and neurocognitive toxicity directly impacts overall functioning and quality of life. There are multiple disease- and host-related factors that influence the development of cancer-related neurocognitive dysfunction, which can progress over time and lead to significant functional impairments. This article provides an overview of the types of neurocognitive deficits seen in survivors of childhood brain tumors, the tools used to assess neurocognitive function, and the factors that impact its severity. This provides a framework for consideration of potential areas for primary prevention by reducing treatment-related toxicity as well as interventions, using behavioral and pharmacologic treatments.
Department of Neurology, Children's Hospital Boston, Boston, MA, USA. nicole.ullrich@childrens.harvard.edu
Nicole J
NJ
Ullrich
Leanne
L
Embry
D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001932:Brain Neoplasms / Q000150:complications* / Q000628:therapy; D002648:Child; D003072:Cognition Disorders / Q000209:etiology*; D006801:Humans; D019635:Neurosurgical Procedures / Q000009:adverse effects*; D011878:Radiotherapy / Q000009:adverse effects*; D017741:Survivors
D000970:Antineoplastic Agents